MIB-626

MIB-626 is an oral microcrystalline form of β-nicotinamide mononucleotide (NMN), developed by Metro International Biotech (MetroBiotech), a private company co-founded by longevity researcher David Sinclair. It is a small-molecule NAD+ precursor, meaning the body converts it into NAD+, a coenzyme cells need for energy metabolism and DNA repair, and one that declines with age. The microcrystalline solid form is MetroBiotech's proprietary hook, because generic NMN itself is not composition-of-matter patentable and is already sold widely as a nutraceutical. Development is spread across at least five active or completed Phase 1/2 studies covering diabetic kidney disease, coronary artery bypass graft (CABG) surgery recovery, exercise capacity, COVID-19 recovery, and Alzheimer's disease [1][2][3][4][5]. The Alzheimer's-specific node here maps to NCT05040321, a Phase 1 pharmacokinetic study (n=22) asking whether oral MIB-626 crosses the blood-brain barrier at concentrations that could plausibly affect brain NAD+ pools [1]. No efficacy readout in Alzheimer's exists. The one completed and reported human MIB-626 trial (COVID-19/AKI) safely raised blood NAD+ but did not improve any clinical or biomarker outcome versus placebo, including serum cystatin C [12]. Broader oral-NMN human research has produced pharmacokinetic wins but no clinically decisive outcome trial in any indication [6]. Commercial competition in Alzheimer's is now dominated by anti-amyloid antibodies lecanemab and donanemab, which set a high bar on trial design, effect size, and payer negotiations for any new mechanism trying to enter the space.

MIB-626 is a novel small molecule, a proprietary microcrystalline NMN solid form designed to improve oral stability and bioavailability of a molecule that is otherwise sold as a nutraceutical [13]. The compound has not been approved for any indication in any geography. The Alzheimer's arm (NCT05040321) is Phase 1, sponsored by Brigham and Women's Hospital, and is a mechanistic CSF penetration study, not a treatment trial [1]. This node's structured phase field is set to 1 to match that trial. The exercise-capacity study (NCT05878119, n=124) had VO2 max as its primary endpoint and is sponsored directly by MetroBiotech; the trial is listed as completed but no peer-reviewed or press-release results were locatable at the time of writing [4]. The diabetic kidney disease study (NCT05759468, n=156) is recruiting and reads out on urine albumin-to-creatinine ratio (UACR) change over six months [3]. The CABG surgery trial (NCT07013591, n=90) uses myocardial tissue NAD+ concentration as its primary endpoint, arguably the most direct test of target engagement in the entire program [2]. The COVID-19 Phase 2a (NCT05038488, n=42) has published results (2025): MIB-626 was safe and substantially raised blood NAD+ and plasma NAD+ metabolites versus placebo, but changes in serum creatinine, cystatin C, other AKI markers, inflammation, and clinical severity did not differ between groups [5][12]. That is a pharmacokinetic win and a clinical null. MetroBiotech has not publicly disclosed FDA breakthrough therapy, fast track, orphan drug, or accelerated approval designations for any indication. A definitive Phase 3 signal in Alzheimer's is not on any public timeline and would likely be 2028 or later given no Phase 2 efficacy trial in AD has been registered.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses to run energy metabolism, and to fuel DNA repair enzymes and sirtuins, a family of NAD+-consuming proteins that regulate cellular stress responses. NAD+ levels fall with age and in several chronic diseases, and boosting NAD+ has become a popular therapeutic hypothesis. NMN is the immediate biochemical precursor to NAD+. Cells absorb NMN and enzymes called NMNATs (nicotinamide mononucleotide adenylyltransferases) attach an adenine group to convert NMN into NAD+ [7]. The Alzheimer's mechanistic chain runs through sirtuins. SIRT1, the best-studied member, uses NAD+ to remove acetyl groups from target proteins. In preclinical models SIRT1 deacetylates tau, which is thought to reduce the formation of neurofibrillary tangles, and SIRT1 upregulates ADAM10 (alpha-secretase), which cleaves amyloid precursor protein (APP) in a non-amyloidogenic direction and reduces production of amyloid-beta. More NAD+ means more available sirtuin activity, which is the theory of change for feeding NMN to an AD brain. This chain has preclinical support from the Sinclair lab and others but has never been demonstrated end-to-end in human Alzheimer's patients. MIB-626 specifically is a microcrystalline solid form: the hypothesis is that the crystalline packing improves chemical stability and slows dissolution enough that meaningful intact NMN reaches enterocytes before it is hydrolyzed to nicotinamide in the gut lumen. That formulation claim matters because NMN and nicotinamide use different cellular uptake routes and route directly to different downstream metabolic pools. Independent oral NMN pharmacokinetic data (Irie et al. 2020, using generic NMN in healthy Japanese men) has been used to argue that most oral NMN is hydrolyzed pre-absorption, which if true would collapse the MIB-626 differentiation story [11]. Genetic evidence for the broader NAD+/neuron axis is indirect: NMNAT1 loss-of-function variants cause Leber congenital amaurosis, an inherited blinding disease, which shows NAD+ biosynthesis matters for neuronal survival [8]. That is a long jump from adult Alzheimer's. Human clinical evidence for oral NMN producing cognitive benefit is essentially absent. Yoshino et al. 2021 showed improved muscle insulin sensitivity in prediabetic women using generic (non-MIB-626) NMN, one of the few positive human outcome signals from any NMN trial and a data point on the class rather than on this specific formulation [6]. Elsewhere the literature is dominated by biomarker changes without clinical endpoints, and the one completed MIB-626 randomized trial (NCT05038488) failed to move any clinical marker [12]. The mechanism-to-disease chain is plausible but multi-step, and every intermediate step is contested.

NCT05040321 is Phase 1, single-arm, n=22, with change in CSF concentrations of MIB-626 as the primary endpoint [1]. It is a pharmacokinetic study, not an efficacy study, and cannot answer whether the drug helps Alzheimer's patients. A positive readout means brain exposure is achievable, which unlocks a follow-on efficacy trial. It does not mean the drug works. The rest of the MetroBiotech Phase 2 portfolio has more informative designs. NCT05759468 in diabetic kidney disease is a 156-patient randomized study with 6-month change in UACR as the primary, a validated surrogate for progression [3]. NCT07013591 in CABG surgery patients (n=90) uses direct measurement of NAD+ in myocardial tissue biopsies, the most rigorous target-engagement readout in the program [2]. NCT05878119 in exercise capacity (n=124, listed completed) measured VO2 max, a well-established performance biomarker; no published readout available [4]. NCT05038488 (COVID-19/AKI, n=42) is the one published human MIB-626 randomized trial: it hit its NAD+ pharmacokinetic secondary but missed on serum cystatin C and every other clinical or AKI marker [12]. The Alzheimer's development plan is the least mature of the five indications. The academic PI sponsorship at Brigham for NCT05040321, versus corporate sponsorship by MetroBiotech on the exercise and COVID trials, suggests the Alzheimer's arm is an investigator-initiated study rather than a pivotal company program.

Our model estimates a 5% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant failure mode. Oral NMN human data to date has demonstrated pharmacokinetic effects (plasma NAD+ metabolites rise) but no reproducible clinical outcome benefit in a well-powered randomized trial. The published COVID-19 MIB-626 Phase 2a is the direct instance of this pattern: NAD+ went up, cystatin C and every other clinical endpoint did not move [12]. Independent pharmacokinetic work suggests oral NMN is largely hydrolyzed to nicotinamide before absorption, which would collapse the mechanistic rationale for a specialized NMN formulation over cheap nicotinamide riboside or nicotinamide itself [6][11]. If MIB-626's microcrystalline solid form does not clear that hurdle, the entire program becomes a proprietary version of an over-the-counter supplement. Safety looks modest based on completed Phase 2 data (no black box signals reported), but Alzheimer's specifically requires long-duration dosing in an elderly, comorbid population, and rare or slow-developing toxicities could surface at Phase 3 sample sizes. IP risk is a make-or-break commercial question and could not be fully resolved from public sources at the time of writing. Because generic NMN is a known small molecule, MetroBiotech's commercial defensibility must come from formulation and solid-form patents on the microcrystalline embodiment rather than composition-of-matter on NMN itself [13]. If those formulation patents are narrow, near expiry, or successfully challenged, generic OTC NMN and NR products could enter the same clinical space at nutraceutical pricing even on a positive Phase 3, gutting the pharmaceutical thesis. Investors should treat exact patent numbers, claim scope, and expiry dates as required diligence. Execution and funding risk is real. MetroBiotech is a small private company running a scattered five-indication portfolio without an obvious lead program, no disclosed recent financing round located in public sources, and no announced pivotal-scale pharma partnership. That raises questions about capital allocation and eventual Phase 3 funding. Commercial risk is severe even in a positive scenario. Alzheimer's payers have pushed back on anti-amyloid pricing already, and a metabolic add-on with modest effect size would face aggressive step therapy and likely restrictive coverage [10]. Regulatory precedent for NAD+ precursor drugs does not exist, which cuts both ways on FDA acceptance of surrogate endpoints in a hypothetical pivotal AD program.

Watch the CABG surgery trial (NCT07013591) most closely [2]. Direct measurement of NAD+ concentration in myocardial tissue biopsies is the cleanest target-engagement readout in the MetroBiotech program, and a positive result there would validate that oral MIB-626 actually raises tissue NAD+ in humans, the foundational assumption behind every downstream indication. If that fails, the entire NMN-as-drug thesis takes damage. The published COVID-19 trial already provides one data point in that direction: blood NAD+ rose but no clinical or biomarker outcome improved, which is the exact pattern that would repeat if tissue NAD+ turns out to be biochemically noisy rather than therapeutically meaningful [12]. The diabetic kidney disease trial (NCT05759468) is the closest thing to a real efficacy readout, with a validated surrogate endpoint (UACR) and adequate sample size for a Phase 2 [3]. Alzheimer's development is a distant fifth priority based on trial maturity. The specific study attached to the Alzheimer's therapeutic tag (NCT05040321) is a Phase 1 CSF study that answers a pharmacology question, not a treatment question [1]. Mid-to-late 2026 is the reasonable check-in point for the CABG and DKD readouts, and any belated publication of the exercise VO2 max data (NCT05878119) should be watched for. Alzheimer's-specific efficacy data is unlikely before 2028. MetroBiotech itself is worth tracking as an early NAD+ metabolism company with academic-founder credibility but no approvals, no obvious lead indication, no located recent financing disclosure, and a commercial thesis that lives or dies on formulation IP. A licensing deal or partnership with larger pharma would be a positive signal. Silent progress across five indications without any convincing single-indication data would be a negative one.